These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33428098)

  • 1. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
    Borrirukwisitsak S; Tantayakom P; Katchamart W
    Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
    Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
    Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
    Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of rituximab in the treatment of systemic sclerosis: A literature review.
    Yoshifuji H; Yomono K; Yamano Y; Kondoh Y; Yasuoka H
    Mod Rheumatol; 2023 Nov; 33(6):1068-1077. PubMed ID: 37053127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
    Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
    Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
    Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
    Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
    Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
    Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
    Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
    de Figueiredo Caldas MMV; de Azevedo KPM; de França Nunes AC; de Oliveira VH; Pimenta IDSF; de Araújo IDT; Neto FAB; da Silveira Gonçalves de Oliveira AK; Piuvezam G
    Adv Rheumatol; 2021 Feb; 61(1):15. PubMed ID: 33640020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.
    Moazedi-Fuerst FC; Lackner A; Kreuzer SM; Eller K; Odler B; Kovacs G; Flick H; Talakic E; Hermann J; Venhoff N; Venhoff A; Hafner F; Brodmann M; Jud P; Yazdani-Biuki B; Husic R; Salmhofer W; Stradner MH; Graninger WB; Thiel J; Brezinschek HP
    J Autoimmun; 2024 Jul; 147():103246. PubMed ID: 38788540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
    Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
    Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
    J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
    Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
    Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis.
    Garzanova LA; Ananyeva LP; Koneva OA; Desinova OV; Starovoytova MN; Ovsyannikova OB; Shayakhmetova RU; Glukhova SI
    Dokl Biochem Biophys; 2024 Aug; 517(1):156-165. PubMed ID: 38861145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.